OPEN Health Appoints David P. King as Non-Executive Chairman and Paul Carter as Independent Board Member
LONDON, Nov. 28, 2022 /PRNewswire/ -- OPEN Health, a leading global provider of scientific communication and market access services helping pharmaceutical companies to unlock the full potential of their clinical and commercial assets, majority owned by Astorg, has announced additions to its board of directors, appointing David P. King as non-executive chairman and Paul Carter as an independent board member.
David P. King will be able to draw on his extensive experience within the pharma services industry to support OPEN Health's continued growth and expansion.
"I am honored to be appointed chairman of OPEN Health, and I am excited to partner with the management team and Astorg to support strengthening its position as a global leader in medical affairs and market access. OPEN Health's strong customer relationships and deep commitment to science position it well for continued growth. I look forward to working with OPEN Health's market-leading management team as they continue to provide innovative solutions to positively impact science, medicine, and patients' lives," remarked David.
David P. King served for 13 years as chairman and CEO of LabCorp, where he spearheaded the company's transformation from a pure-play clinical laboratory into a global leader in life sciences, tripling the size of the company to more than $11.5 billion in revenue and nearly 65,000 employees. David was critical in the expansion of offerings for pharmaceutical and biotech companies, including leading the acquisition of Covance. Today, LabCorp is a Fortune 250 company with over $15 billion in revenue and 75,000 employees, serving pharmaceutical companies, doctors, hospitals, researchers, and patients worldwide.
Paul Carter will draw on his diverse commercial experience across multiple international markets and leverage the pharma customer perspective to support OPEN Health's continued dedication to science and customer centricity.
Commenting on his appointment, Paul Carter said, "OPEN Health is a formidable company, and I look forward to working with the board and management team to help guide the company's development plan and further strengthen its position as a leading commercialization partner for pharma and biotech companies globally."
Paul Carter served as executive vice president and chief commercial officer at Gilead, where he oversaw unprecedented growth and commercial success in the US, Europe, Japan, and other geographies. In his prior role as head of commercial operations for international markets at Gilead, Mr. Carter built out the Gilead commercial infrastructure across 38 countries over eight years.